20170543

Inclusion Criteria:

* Men or women greater than or equal to 18 years old.
* Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing.

Exclusion Criteria

* Active brain metastases from non-brain tumors.
* Myocardial infarction within 6 months of study day 1.
* Gastrointestinal (GI) tract disease causing the inability to take oral medication.

Any Site
Colon
Lung

Indiana University (IU)

• Indiana University Hospital / IU Simon Cancer Center

• Sotorasib for Lung Cancers with KRAS p.G12C Mutation
  Skoulidis F;Li BT;Dy GK;Price TJ;Falchook GS;Wolf J;Italiano A;Schuler M;Borghaei H;Barlesi F;Kato T;Curioni-Fontecedro A;Sacher A;Spira A;Ramalingam SS;Takahashi T;Besse B;Anderson A;Ang A;Tran Q;Mather O;Henary H;Ngarmchamnanrith G;Friberg G;Velcheti V;Govindan R;
• KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
  Hong DS;Fakih MG;Strickler JH;Desai J;Durm GA;Shapiro GI;Falchook GS;Price TJ;Sacher A;Denlinger CS;Bang YJ;Dy GK;Krauss JC;Kuboki Y;Kuo JC;Coveler AL;Park K;Kim TW;Barlesi F;Munster PN;Ramalingam SS;Burns TF;Meric-Bernstam F;Henary H;Ngang J;Ngarmchamnanrith G;Kim J;Houk BE;Canon J;Lipford JR;Friberg G;Lito P;Govindan R;Li BT;
• Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
  Fakih MG;Kopetz S;Kuboki Y;Kim TW;Munster PN;Krauss JC;Falchook GS;Han SW;Heinemann V;Muro K;Strickler JH;Hong DS;Denlinger CS;Girotto G;Lee MA;Henary H;Tran Q;Park JK;Ngarmchamnanrith G;Prenen H;Price TJ;
• Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
  Strickler JH;Satake H;George TJ;Yaeger R;Hollebecque A;Garrido-Laguna I;Schuler M;Burns TF;Coveler AL;Falchook GS;Vincent M;Sunakawa Y;Dahan L;Bajor D;Rha SY;Lemech C;Juric D;Rehn M;Ngarmchamnanrith G;Jafarinasabian P;Tran Q;Hong DS;
• Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
  Lanman BA;Allen JR;Allen JG;Amegadzie AK;Ashton KS;Booker SK;Chen JJ;Chen N;Frohn MJ;Goodman G;Kopecky DJ;Liu L;Lopez P;Low JD;Ma V;Minatti AE;Nguyen TT;Nishimura N;Pickrell AJ;Reed AB;Shin Y;Siegmund AC;Tamayo NA;Tegley CM;Walton MC;Wang HL;Wurz RP;Xue M;Yang KC;Achanta P;Bartberger MD;Canon J;Hollis LS;McCarter JD;Mohr C;Rex K;Saiki AY;San Miguel T;Volak LP;Wang KH;Whittington DA;Zech SG;Lipford JR;Cee VJ;
• Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
  Dy GK;Govindan R;Velcheti V;Falchook GS;Italiano A;Wolf J;Sacher AG;Takahashi T;Ramalingam SS;Dooms C;Kim DW;Addeo A;Desai J;Schuler M;Tomasini P;Hong DS;Lito P;Tran Q;Jones S;Anderson A;Hindoyan A;Snyder W;Skoulidis F;Li BT;
• Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary
  Dy GK;Govindan R;Velcheti V;Falchook GS;Italiano A;Wolf J;Sacher AG;Takahashi T;Ramalingam SS;Dooms C;Kim DW;Addeo A;Desai J;Schuler M;Tomasini P;Hong DS;Lito P;Tran Q;Jones S;Anderson A;Hindoyan A;Snyder W;Skoulidis F;Li BT;
• Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC
  Hochmair MJ;Vermaelen K;Mountzios G;Carcereny E;Dooms C;Lee SH;Morocz E;Kato T;Ciuleanu TE;Dy GK;Parente B;O'Byrne KJ;Chu QS;Castro Junior G;Girard N;Snyder W;Tran Q;Kormany W;Houk B;Mehta B;Curioni-Fontecedro A;